Products for Research Use Only

BMS-37

CAT: 0804-HY-150879-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-150879-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor with an IC50 towards the PD-L1/PD-1 complex in the range of 18 to 200 nM. BMS-37 shows unspecific toxicity against modified Jurkat T cells with an EC50 between 3 and 6 µM. BMS-37 can be used for the study of the PD-L1-induced exhaustion of T-cells or as PD-L1 ligand to synthesize PROTAC molecules[1][2][3].
CAS Number
1675202-20-6
UNSPSC
12352005
Target
Ligands for Target Protein for PROTAC; PD-1/PD-L1
Type
Reference compound
Related Pathways
Immunology/Inflammation; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bms-37.html
Purity
98.01
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=CC(OCC2=CC=CC(C3=CC=CC=C3)=C2C)=CC(OC)=C1CNCCNC(C)=O
Molecular Formula
C27H32N2O4
Molecular Weight
448.55
References & Citations
[1]Yang L, et, al. Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma. Chinese Chemical Letters. 2022 Aug 20: 107762.|[2]Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) . Oncotarget. 2016 May 24;7 (21) :30323-35.|[3]Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8 (42) :72167-72181.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported